CDC drug-resistant germs report 2026 findings put a stark number on a problem doctors have warned about for years: an estimated 9.7 million drug-resistant infections and about 50,800 deaths a year in the United States. The Centers for Disease Control and Prevention (CDC) released its 2026 Antimicrobial Resistance Threats Report on 27 October 2026, trending per news coverage, using data from 2023. It is the agency's most comprehensive assessment of its kind, and its first threats report since 2019. The headline numbers are alarming, but the CDC's own caution matters just as much: because the agency expanded its data sources and changed its methods, the new estimates should not be compared directly with the 2019 report. Some germs really are rising fast. Some of the higher total also reflects better counting. Both things can be true at once, and understanding the difference is the key to reading this report honestly.
Antimicrobial resistance happens when bacteria, fungi and other germs evolve ways to survive the medicines designed to kill them. Antibiotics stop bacterial infections. Antifungals stop fungal infections. When germs resist those drugs, infections that were once routine to treat can become longer, harder and sometimes impossible to treat. Surgery, cancer treatment, organ transplants and care for premature babies all depend on antibiotics working. That is why CDC Director Dr Erica Schwartz said in a statement carried with the report: "Antimicrobial resistance threatens modern medicine and puts millions of Americans at risk every year." She added: "This data shows both the progress we've made and the significant work that remains."
What the CDC drug-resistant germs report 2026 found
The CDC drug-resistant germs report 2026 examined 19 drug-resistant bacterial and fungal pathogens and sorted them into three tiers. Four were classed as urgent threats, meaning they require urgent and aggressive action. Thirteen were classed as serious threats, requiring prompt and sustained action. Two were classed as concerning threats, requiring careful monitoring and prevention. The agency also published a watch list of six additional pathogens whose full burden is not yet understood. Together, the 19 pathogens were estimated to cause 9.7 million infections and 50,800 deaths each year in the United States. Healthcare-associated infections accounted for more than 42,000 of those deaths, according to reporting of the CDC figures, with nearly 12 billion dollars in costs linked to healthcare-associated infections in 2023.
To rank the threats, the CDC said it used seven factors: clinical impact, economic impact, the current number of new infections in the United States, the projected change in new infections over the next five years, transmissibility, preventability and the availability of effective antibiotics, antifungals and other treatments. That broader method is one reason the agency warns against a simple comparison with 2019. The previous report, published in 2019 but based on 2013 data, estimated more than 2.8 million antimicrobial-resistant infections and more than 35,000 deaths a year. The 2026 report uses 2023 data and draws on more surveillance sources. Dawn M. Sievert, senior science advisor for the CDC's Antimicrobial Resistance Coordination and Strategy Unit, told Healio that the agency was recognising a substantial increase, but that direct comparison with the 2019 numbers would be misleading because data sources, methods and analysis had all been updated.
The 4 urgent threats in the CDC drug-resistant germs report 2026
The four urgent threats are the same four that topped the previous list, the CDC noted. They are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales (CRE) and drug-resistant Neisseria gonorrhoeae. Each earns its place for a different reason, and together they show how resistance reaches hospitals, communities and clinics.
Candida auris, also now called Candidozyma auris, is a fungus that spreads in healthcare settings, can live on patients' skin without causing symptoms, and can contaminate surfaces and medical equipment such as catheters. The report counted 4,523 cases in the United States in 2023, about ten times the number in 2019, with cases rising by more than 50 percent between 2022 and 2023 alone. The CDC said some strains resist all three available classes of antifungal treatment. Tom Chiller, former chief of the CDC's Mycotic Diseases Branch, told CIDRAP News that C. auris infections are fatal in 29 percent to 62 percent of patients, and that the limited number of antifungal medicines makes treatment difficult. He said more drug development was needed, alongside work on decolonising patients, disinfecting healthcare environments quickly and screening patients and settings more widely.
Carbapenem-resistant Enterobacterales, or CRE, are a family of bacteria resistant to carbapenems, a class of antibiotics often used as a last resort. In 2023, CRE caused an estimated 14,878 infections in hospitalised patients and 1,252 deaths, according to the report. A separate CDC study published in September 2025 found that CRE incidence in United States hospitals rose 18 percent from 2019 to 2023. The most worrying subgroup carries the New Delhi metallo-beta-lactamase (NDM) resistance gene. NDM-CRE infections rose by more than 460 percent between 2019 and 2023 in that separate study, which used data from 29 states and did not include several heavily populated states, including California, Florida, New York and Texas, so the true national increase may be higher. The CDC has described NDM-CRE infections, including pneumonia, bloodstream infections, urinary tract infections and wound infections, as extremely hard to treat and potentially deadly, and has warned that detection is challenging because many clinical laboratories lack the necessary testing capacity.
Carbapenem-resistant Acinetobacter is another hospital threat, particularly for patients with ventilators, catheters and other indwelling devices. Like CRE, it can share resistance with other bacteria, which is one reason the CDC highlights the rapid spread of resistance genes, not only the spread of individual germs. Drug-resistant gonorrhoea, the fourth urgent threat, shows the community side of the problem. Gonorrhoea is a sexually transmitted infection caused by Neisseria gonorrhoeae. Without effective treatment, it can cause pelvic inflammatory disease, ectopic pregnancy and infertility, and it can increase the risk of HIV infection. Resistance narrows the treatment options for an infection that is already common and often has no symptoms at first.
The 13 serious threats and 2 concerning threats
The 13 serious threats are Clostridioides difficile (C. diff), drug-resistant Campylobacter, drug-resistant Candida, drug-resistant Mycobacterium tuberculosis, drug-resistant Neisseria meningitidis, drug-resistant nontyphoidal Salmonella, drug-resistant Salmonella Typhi, drug-resistant Shigella, drug-resistant Streptococcus pneumoniae, extended-spectrum cephalosporin-resistant Enterobacterales, methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Pseudomonas aeruginosa and vancomycin-resistant Enterococcus (VRE). The two concerning threats are clindamycin-resistant group B Streptococcus and drug-resistant group A Streptococcus.
Several names on the serious list will be familiar to anyone who has followed food safety or hospital care. Drug-resistant Campylobacter is a leading cause of foodborne illness. MRSA and VRE are long-standing hospital concerns. Drug-resistant tuberculosis matters because tuberculosis treatment already takes months, and resistance makes it longer, more toxic and less certain. Drug-resistant Shigella spreads through contaminated food and water and has become increasingly associated with sexual activity, according to CIDRAP's reporting of the CDC findings. The watch list adds six more pathogens to monitor: azole-resistant Aspergillus fumigatus, drug-resistant Bordetella pertussis, drug-resistant dermatophytes, drug-resistant Haemophilus influenzae, drug-resistant Mycoplasma genitalium and nontuberculous mycobacteria. Three of those — drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria — were added to the watch list in this report.
One addition to the serious list deserves attention on its own. Drug-resistant Neisseria meningitidis, which can cause meningococcal disease, a rare but life-threatening illness, was newly classed as a serious threat after drug-resistant infections were found in community settings. The CDC said the estimated number of ciprofloxacin-resistant cases more than doubled between 2019 and 2023, and the estimated number of penicillin-resistant cases tripled. The pathogen caused an estimated 787,000 drug-resistant infections in 2023, with more than 214 million dollars in total lifetime medical costs for all infections diagnosed that year, according to Healio's reporting of the CDC data.
Why the CDC drug-resistant germs report 2026 warns against direct comparisons
The warning against comparing the new totals with 2019 is not a footnote. It changes how the report should be described. If the 9.7 million figure is presented as proof that infections more than tripled since 2019, that overstates what the CDC itself claims. The agency expanded surveillance, added data sources and revised its analytics. Some increases are real and documented pathogen by pathogen, such as the tenfold rise in C. auris cases and the surge in NDM-CRE. Others may partly reflect cases that were previously missed. Infectious Diseases Society of America President Wendy Armstrong said in a statement that the numbers were alarming by any measure, but particularly sobering when infectious diseases physicians connected real patients with the statistics in everyday practice. The honest summary is therefore twofold: the burden is very large, and the trend for several specific germs is clearly upward, even if the overall total cannot be placed neatly beside the 2019 total.
There is also genuine good news in the report, and the CDC points to it as evidence that prevention works. C. difficile was downgraded from an urgent threat to a serious threat. The bacterium causes severe diarrhoea and damage to the colon, and the CDC notes that it is not typically drug-resistant itself, but is driven by the same factors that drive resistance: antibiotic use and the spread of germs. C. difficile still caused 412,504 cases in 2023, with more than 11,000 deaths among hospitalised cases, according to the report. Yet infections fell by 9 percent from 2018 to 2023, and the CDC attributes the decline to better infection control and improved antibiotic use in hospitals. Sievert told Healio that rates fell 21 percent overall from 2018 to 2020 and then remained stable in healthcare settings from 2020 to 2023. Her conclusion, quoted by Healio, was direct: progress against C. difficile shows that a comprehensive public health response, grounded in targeted infection prevention, antibiotic stewardship, diagnostic excellence and increased treatment options, works.
What the report means for hospitals, doctors and patients
For hospitals, the report reinforces work that is already under way but far from finished: hand hygiene, cleaning and disinfection, screening patients at risk, isolating carriers of resistant germs, and using antibiotics only when needed, at the right dose and for the right length of time. The C. difficile story shows that those unglamorous measures add up. The C. auris and CRE stories show what happens when they fall short, especially where patients are seriously ill, have devices such as ventilators and catheters, or move between hospitals, nursing homes and other care settings. Genomic surveillance, which tracks resistance genes as they move between germs and facilities, is another priority named by public health and medical groups responding to the report, alongside broader infection-control funding.
For doctors and researchers, the report strengthens the case for new antibiotics and antifungals, and for financial incentives to develop them. Public health groups cited the PASTEUR Act, a proposed United States law intended to revive antibiotic and antifungal development, in responses to the report. Developing a new antibiotic is commercially difficult: a good new drug should be used sparingly to preserve its effectiveness, which limits sales. That market failure is why experts argue that subscription-style payments or other incentives, rather than sales volume alone, are needed to keep new treatments coming. The report does not itself pass any law, but it supplies the evidence that advocates will cite.
For readers, the practical message is steadier than any single headline. Antibiotics do not treat viral infections such as the common cold or flu. Taking antibiotics when they are not needed, stopping a prescribed course early without medical advice, or sharing leftover antibiotics can all help resistance grow. Vaccination, hand hygiene and safe food handling reduce infections in the first place, which reduces the need for antibiotics at all. People with symptoms that could be a resistant infection, a wound that is not healing, a urinary infection that returns after treatment, or a sexually transmitted infection, should seek medical care rather than self-treating. This article is general information only, not medical advice, and anyone with a personal health concern should talk to their own clinician. The wider lesson of the report is not panic, but persistence: the same prevention and stewardship that pushed C. difficile down can be applied, pathogen by pathogen, to the germs that are still climbing. That work is slower than a headline, and it is the work the CDC is asking hospitals, prescribers and the public to sustain.
Related coverage on Worldlession includes the Congo Ebola outbreak passing 10,000 cases in 2026 and the Ebola vaccine trial testing the first Bundibugyo shots in the DRC, which show how infection control and vaccination shape the course of a very different outbreak.
Sources: CDC 2026 Antimicrobial Resistance Threats Report, released 27 October 2026, as reported by Healio on 27 October 2026; NBC Chicago reporting on the CDC report and the rapid spread of resistance genes, 27 October 2026; CIDRAP News reporting on the CDC report, C. auris, CRE and C. difficile figures, 27 October 2026; Becker's Hospital Review listing of the 19 pathogens by threat tier, 27 October 2026; and the CDC's September 2025 NDM-CRE study as summarised in reporting on 27-28 October 2026. Figures for infections and deaths are CDC estimates based on 2023 data; the CDC cautions against direct comparison with its 2019 report because data sources and methods were updated.